On Mar. 15, 2021, Resverlogix announced the publishing of a new article titled: ﾓBromodomain and extraterminal protein inhibitor, apabetalone (RVX-208), reduced ACE2 expression and attenuates SARS-CoV-2 infection in vitroﾔ, on the pre-print server, bioRxiv. The findings, made in collaboration with Dr. Dalia ElGamalﾒs research group at the University of Nebraska Medical Center (UNMC), provided a strong rationale for use of apabetalone, a bromodomain and extraterminal (BET) protein inhibitor, as a therapeutic for COVID-19.